The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract
about
Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesisMechanistic Insights into the Hydrolysis and Synthesis of Ceramide by Neutral CeramidaseCharacterization and subcellular localization of murine and human magnesium-dependent neutral sphingomyelinaseHuman acid ceramidase: processing, glycosylation, and lysosomal targetingRat intestinal ceramidase: purification, properties, and physiological relevance.Identification of Mg2+ -dependent neutral sphingomyelinase 1 as a mediator of heat stress-induced ceramide generation and apoptosis.Changes of activity and isoforms of alkaline sphingomyelinase (nucleotide pyrophosphatase phosphodiesterase 7) in bile from patients undergoing endoscopic retrograde cholangiopancreatographyGenerating ceramide from sphingomyelin by alkaline sphingomyelinase in the gut enhances sphingomyelin-induced inhibition of cholesterol uptake in Caco-2 cells.Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice.Pancreatic trypsin cleaves intestinal alkaline sphingomyelinase from mucosa and enhances the sphingomyelinase activity.Human meconium contains significant amounts of alkaline sphingomyelinase, neutral ceramidase, and sphingolipid metabolites.Expression of alkaline sphingomyelinase in yeast cells and anti-inflammatory effects of the expressed enzyme in a rat colitis model.Crucial role of alkaline sphingomyelinase in sphingomyelin digestion: a study on enzyme knockout mice.Absorption and lipoprotein transport of sphingomyelin.Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation?Physiological functions and clinical implications of sphingolipids in the gut.Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.Investigation into the dosage of dietary sphingomyelin concentrate in relation to the improvement of epidermal function in hairless mice.A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease.Intestinal absorption of dietary maize glucosylceramide in lymphatic duct cannulated rats.The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.Preparation of (13)C-labeled ceramide by acetic acid bacteria and its incorporation in miceSea cucumber cerebrosides and long-chain bases from Acaudina molpadioides protect against high fat diet-induced metabolic disorders in mice.Dietary milk fat globule membrane improves endurance capacity in mice.Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells.Sphingomyelin hydrolysis in the gut and clinical implications in colorectal tumorigenesis and other gastrointestinal diseases.Ursodeoxycholic acid increases the activities of alkaline sphingomyelinase and caspase-3 in the rat colon.Sphingolipids in the gut? Which are the important issues?
P2860
Q24653460-595F4BDE-CF4A-46A1-B4DF-D2DACB22FCB8Q27653166-4A1E9B69-0EB2-4AE8-9436-AAEC173B50CDQ28145113-59C45D90-D14C-4451-8DCE-8B9B2AB97038Q28206182-4B3084A1-E5BD-4EC8-96A5-9E98304AE2F4Q31082733-71DDCB81-AD20-4C0E-899E-598ACC2D1AC4Q33357486-F894DA67-A553-42C3-9E92-323BA36BB580Q34078002-5355D7C6-3AEA-4942-8C6B-5CC880AB6E3AQ34110288-37F7F6CA-62DF-4A91-86E4-FC7D47D8B89FQ34320069-CA77D4DA-4AEB-4466-A281-511ADF3D59E7Q34327666-6E3A1FB5-BC17-4020-9091-979F2787D03FQ34599585-3B9916D8-0EE4-4FC4-A566-575EA97E7A88Q34874519-AC2AC259-0122-483D-ADAC-17655D9368B7Q35771158-DAD33D94-7715-4239-AD2D-DFF410A951ADQ36298122-9145B012-ED5B-4434-87F3-81CFC6B9AA09Q36619585-8D98DECF-7D3B-491A-9493-55827015B07AQ37852814-0CE051B3-CD2A-4EED-B1AE-5019FB364604Q37858901-0C4AFA3F-2B0B-4A56-98DA-A38D6E413260Q37880161-EF262D7A-5394-49CA-8E13-DC56163CB662Q39117551-20B7E818-C84B-40F9-B9D2-FC20B64009A7Q39651519-41AB13D1-187E-4A30-8B81-82F97404962CQ40948826-1332003C-A844-452E-995B-5510757868F4Q41533061-2C6F36DB-61CA-4B86-882F-B4F72C8A2061Q41833396-C9E46838-FC83-479D-AF58-60C82BF1E1B6Q42139418-210D2341-4E73-440C-BBA6-9A3B351A6554Q51701377-7FCDE1A4-1166-4C1B-B794-C9062C05158BQ53085881-03D9A19D-E178-4BE4-AE85-FC7E45FDCD65Q53431662-B40EFC56-A9EE-4E69-B0F0-83057F75EC5FQ53884158-8F060C9F-9E14-4808-9B99-993F5A8C62B0Q57351177-DAD15F1D-B3A5-4312-A95B-05F60C11D566
P2860
The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 1969
@uk
name
The presence of sphingomyelin- ...... in the small intestinal tract
@en
The presence of sphingomyelin- ...... in the small intestinal tract
@nl
type
label
The presence of sphingomyelin- ...... in the small intestinal tract
@en
The presence of sphingomyelin- ...... in the small intestinal tract
@nl
prefLabel
The presence of sphingomyelin- ...... in the small intestinal tract
@en
The presence of sphingomyelin- ...... in the small intestinal tract
@nl
P1476
The presence of sphingomyelin- ...... in the small intestinal tract
@en
P304
P356
10.1016/0005-2760(69)90192-1
P50
P577
1969-03-01T00:00:00Z